The current stock price of ICU is 2.58 USD. In the past month the price increased by 9.69%. In the past year, price decreased by -83.57%.
ChartMill assigns a technical rating of 1 / 10 to ICU. When comparing the yearly performance of all stocks, ICU is a bad performer in the overall market: 98.07% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to ICU. While ICU seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months ICU reported a non-GAAP Earnings per Share(EPS) of -8.4. The EPS increased by 32.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -87.99% | ||
| ROE | -119.2% | ||
| Debt/Equity | 0 |
5 analysts have analysed ICU and the average price target is 10.2 USD. This implies a price increase of 295.35% is expected in the next year compared to the current price of 2.58.
For the next year, analysts expect an EPS growth of 20.49% and a revenue growth 601.24% for ICU
SeaStar Medical Holding Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Denver, Colorado and currently employs 19 full-time employees. The company went IPO on 2021-01-26. SeaStar Medical Holding Corporation is a commercial-stage medical technology company, which is focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The company has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).
SEASTAR MEDICAL HOLDING CORP
3513 Brighton Blvd, Suite 410
Denver COLORADO US
Employees: 19
Phone: 18444278100
SeaStar Medical Holding Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Denver, Colorado and currently employs 19 full-time employees. The company went IPO on 2021-01-26. SeaStar Medical Holding Corporation is a commercial-stage medical technology company, which is focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The company has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).
The current stock price of ICU is 2.58 USD. The price decreased by -0.39% in the last trading session.
ICU does not pay a dividend.
ICU has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
ICU stock is listed on the Nasdaq exchange.
SEASTAR MEDICAL HOLDING CORP (ICU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.4).
SEASTAR MEDICAL HOLDING CORP (ICU) has a market capitalization of 93.01M USD. This makes ICU a Micro Cap stock.